MorphoSys AG (ETR:MOR) has been given a €76.00 ($90.48) price objective by stock analysts at Commerzbank Ag in a research note issued on Thursday. The firm currently has a “buy” rating on the stock.
Several other research firms also recently commented on MOR. Berenberg Bank set a €68.00 ($80.95) price objective on MorphoSys AG and gave the company a “buy” rating in a research note on Thursday, May 25th. Independent Research GmbH set a €77.00 ($91.67) target price on MorphoSys AG and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) target price on MorphoSys AG and gave the stock a “neutral” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of €70.38 ($83.78).
Shares of MorphoSys AG (ETR:MOR) opened at 69.81 on Thursday. The firm’s market capitalization is €2.02 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90. The firm has a 50-day moving average price of €60.74 and a 200 day moving average price of €59.75.
COPYRIGHT VIOLATION NOTICE: “MorphoSys AG (MOR) Given a €76.00 Price Target by Commerzbank Ag Analysts” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/09/21/morphosys-ag-mor-given-a-76-00-price-target-by-commerzbank-ag-analysts.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.